Pealkiri: 

Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial

Autorid: Veerus P , Fischer K , Hovi SL , Karro H , Rahu M , Hemminki E
Väljaandja/tellija: BMC Women's Health
Märksõnad: hormoonasendusravi, elukvaliteet, naised
Välja antud: 2008
Tüüp: Teaduslik artikkel/kogumik
Viide: Veerus P, Fischer K, Hovi SL, et al. Symptom reporting and quality of life in the Estonian Postmenopausal Hormone Therapy Trial. BMC Women's Health 2008;8(5):1-10.
Link: http://www.biomedcentral.com/content/pdf/1472-6874-8-5.pdf
Alamvaldkonnad:Mittenakkushaigused
Reproduktiivtervis
Tervisepoliitika rakendamine ja hindamine
Kirjeldus: Background: The aim of the study was to determine the effect of postmenopausal hormone therapy on women's symptom reporting and quality of life in a randomized trial.
Methods: 1823 women participated in the Estonian Postmenopausal Hormone Therapy (EPHT) Trial between 1999 and 2004. Women were randomized to open-label continuous combined hormone therapy or no treatment, or to blind hormone therapy or placebo. The average followup period was 3.6 years. Prevalence of symptoms and quality of life according to EQ-5D were assessed by annually mailed questionnaires.
Results: In the hormone therapy arms, less women reported hot flushes (OR 0.20; 95% CI: 0.14-0.28), sweating (OR 0.56; 95% CI: 0.44-0.72), and sleeping problems (OR 0.66; 95% CI: 0.52-0.84), but more women reported episodes of vaginal bleeding (OR 19.65; 95% CI: 12.15-31.79). There was no difference between the trial arms in the prevalence of other symptoms over time. Quality of life did not depend on hormone therapy use.
Conclusion: Postmenopausal hormone therapy decreased vasomotor symptoms and sleeping problems, but increased episodes of vaginal bleeding, and had no effect on quality of life.